| Reply to “Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in HBV patients” |
| Pin-Nan Cheng1, Ming-Lung Yu2,3 |
1Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
2Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital; College of Medicine and Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University, Kaohsiung, Taiwan
3School of Medicine and Doctoral Program of Clinical and Experimental Medicine, College of Medicine and Center of Excellence for Metabolic Associated Fatty Liver, National Sun Yat-sen University, Kaohsiung, Taiwan |
| Correspondence : |
Ming-Lung Yu ,
Tel: +886-7-312-1101 ext. 7475, Fax: +886-7-312-3955, Email: fish6069@gmail.com
|
|
|
Received: April 5, 2024 Accepted: April 9, 2024 |
|
|
|
|
PDF Links
Full text via DOI
Download Citation
